RE: Partnership boasts a substantial budget of €81 million Euros18 Jan 2024 20:16
LONDON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Genflow Biosciences Plc (Genflow or the "Company”) (LSE:GNF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing process, in collaboration with Revatis SA and EXO Biologics, is proud to announce the initiation of two significant research programs backed by substantial non-diluting and non-reimbursable research grants by the Government of Wallonia in Belgium. Both of these strategic initiatives will strengthen Genflow’s position at the forefront ageing-related research, and its mission to improve the health and well-being of older adults.